Consolidated Financial Results
for the Three Months Ended June 30, 2026
(Based on Japanese GAAP)

August 6, 2026

Company name:	TOWA PHARMACEUTICAL CO., LTD.			
Stock exchange listing:	Tokyo			
Stock code:	4553 URL https://www.towayakuhin.co.jp/			
Representative:	President and Representative Director	Itsuro Yoshida		
Inquiries:	Director	Toshikazu Kokubun	TEL 06-7175-8570	

Scheduled date to commence dividend payments: —

Preparation of supplementary material on financial results: Yes

Holding of quarterly financial results meeting: Yes (for analysts and institutional investors)

(Amounts less than one million yen are rounded down)

1. Consolidated financial results for the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated operating results (cumulative)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended June 30, 2026	71,380	9.6	6,519	25.2	7,941	100.9	5,531	120.1
Three months ended June 30, 2025	65,149	4.1	5,206	(8.2)	3,953	(54.0)	2,513	(54.3)

Note : Comprehensive income For the three months ended June 30, 2026 : ¥6,350 million [107.1%]
For the three months ended June 30, 2025 : ¥3,065 million [(64.2)%]

	Earnings per share	Diluted earnings per share
	Yen	Yen
Three months ended June 30, 2026	112.36	—
Three months ended June 30, 2025	51.06	—

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	Millions of yen	Millions of yen	%
As of June 30, 2026	480,709	182,476	38.0
As of March 31, 2026	475,290	178,103	37.5

Reference : Equity As of June 30, 2026 : ¥182,476 million
As of March 31, 2026 : ¥178,103 million

2. Cash dividends

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2026	—	40.00	—	40.00	80.00
Year ending March 31, 2027	—				
Year ending March 31, 2027 (Forecast)		40.00	—	45.00	85.00

Note : Revisions to the forecasts of cash dividends most recently announced : None
The above "Dividends" section relates to dividends on the Company's common shares. Please refer to "Dividends of Class Shares" below for dividends for unlisted class shares with rights different from those of the common shares issued by the Company.

3. Forecast of consolidated financial results for the year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending September 30, 2026	145,700	11.7	12,700	21.6	11,700	(2.3)	8,100	(1.4)	163.02
Full year	304,000	11.1	32,000	38.5	30,000	6.8	21,500	309.5	430.77

Note : Revisions to the forecasts of consolidated financial results most recently announced : None

4. Notes

(1) Changes in significant subsidiaries during the three months ended June 30, 2026 (changes in specified subsidiaries resulting in the change in scope of consolidation): None

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements

Changes in accounting policies due to revisions to accounting standards and other regulations: None

Changes in accounting policies due to other reasons: None

Changes in accounting estimates: None

Restatement of prior period financial statements: None

(4) Number of issued shares (common shares)

Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2026	51,516,000 shares	As of March 31, 2026	51,516,000 shares

Number of treasury shares at the end of the period

As of June 30, 2026	2,288,133 shares	As of March 31, 2026	2,288,133 shares

Average number of shares during the period (cumulative from the beginning of the fiscal year)

Three months ended June 30, 2026	49,227,867 shares	Three months ended June 30, 2025	49,227,097 shares

* This report of financial results is unaudited.

*Explanation Concerning the Appropriate Use of Financial Results Forecasts and Other Special Instructions

(Caution regarding forward-looking statements)

The forecast of financial results and forward-looking statements contained in this report are based on information currently available to the Company as well as certain assumptions that it judges to be reasonable. Actual results may differ materially due to a variety of factors. For the assumptions used in forecasts and precautionary statements regarding the use of the forecasts, please refer to “1. Overview of Operating Results and Financial Position (3) Explanation of consolidated financial forecasts and other forward-looking information” on page 5 of the accompanying materials.

(Method of Obtaining Financial Results Supplementary Materials)

Financial results supplementary materials are posted via TDnet on the date of disclosure.

Dividends of Class Shares

The breakdown of dividends per share on class shares with rights different from those of the common shares is as follows.

(Series 1, Class A Preferred Stock)

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ending March 31, 2027	—				
Year ending March 31, 2027 (Forecast)		7,474.00	—	21,939.70	29,413.70

Note : The Series 1, Class A Preferred Stock was issued on July 31, 2026.

(Series 2, Class A Preferred Stock)

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ending March 31, 2027	—				
Year ending March 31, 2027 (Forecast)		—	—	—	—

Note : The dividend forecast for the Series 2, Class A Preferred Stock for the fiscal year ending March 2027 has not been determined at this point as it has not yet been issued.

Contents

1. Overview of Operating Results and Financial Position

The forward-looking statements in this document are based on judgments made as of the end of the period under review.

(1) Overview of operating results during the period

With the corporate philosophy of “Contribute to people’s health and dedicate ourselves to people's genuine smiles,” the Group has been working on various issues. The aim is to establish a foundation in new markets and new businesses and realize group synergies with each subsidiary while making the domestic generic drug business its core business in accordance with the “6th Medium-term Business Plan 2024–2026 PROACTIVE III” announced in June 2024.

As a result, operating results in the consolidated three months under review are as follows.

Consolidated earnings (Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026	Change	Change (%)
Net sales	65,149	71,380	6,230	9.6%
Cost of sales	41,474	45,281	3,806	9.2%
Gross profit	23,674	26,099	2,424	10.2%
Selling, general and administrative expenses	18,468	19,579	1,111	6.0%
Operating profit	5,206	6,519	1,312	25.2%
Ordinary profit	3,953	7,941	3,988	100.9%
Profit attributable to owners of parent	2,513	5,531	3,017	120.1%

Both net sales and profit were up due to an increase in sales volume as well as unit price at Towa Pharmaceutical and growth in sales in the European B2C and B2B businesses at Towa Pharma International Holdings, S.L. (hereinafter referred to as “Towa INT”), which offset the weaker performance of Sunsho Pharmaceutical Co., Ltd.

Net sales were 71,380 million yen (up 9.6% year on year), operating profit came to 6,519 million yen (up 25.2% year on year), ordinary profit was 7,941 million yen (up 100.9% year on year) due to a gain of 1,424 million yen on valuation of derivatives, and profit attributable to owners of parent totaled 5,531 million yen (up 120.1% year on year).

Results by segment are as follows. Segment profit of the reporting segments is the figure before amortization of goodwill.

Results by segment (Millions of yen)

	Domestic segment				Overseas segment			
	Three months ended June 30, 2025	Three months ended June 30, 2026	Change	Change (%)	Three months ended June 30, 2025	Three months ended June 30, 2026	Change	Change (%)
Net sales	52,780	55,981	3,201	6.1%	12,492	15,612	3,119	25.0%
Segment profit (loss)	6,873	7,013	140	2.0%	(562)	5	568	—

(Note) Segment profit (loss) is based on operating profit.

(Domestic segment)

In the generic drug industry in Japan, in March 2024, the Medical Insurance Committee of the Social Security Council set the main goal of increasing the volume share of generic drugs to 80% or more in all prefectures by the end of FY2029 while maintaining a stable supply of drugs. It also set a new secondary goal of increasing the value share of generic drugs to 65% or more by the end of FY2029. In addition, the introduction of the selective treatment system for long-listed drugs began in October 2024. Choosing this option requires an additional co-payment for some brand-name drugs for which generic drugs are available. As a result, the volume share of generic drugs in January-March 2026 reached 90.3% (according to the Japan Generic Medicines Association).

In the meantime, annual drug price revisions since FY2021 have been making the situation extremely severe for the pharmaceutical industry. Furthermore, due to a series of supply concerns stemming from quality problems at multiple generic drug companies that came to light in 2020, confidence in generic drugs has declined and the environment facing the generic drug industry has become increasingly tough.

Under these circumstances, the “Report of the Study Group on Industrial Structure for Achieving Stable Supply of Generic Drugs” published by the Ministry of Health, Labour and Welfare in May 2024 showed that the government will “establish an intensive reform period of about five years to ensure a manufacturing management and quality control system, secure stable supply capacity, and realize a sustainable industrial structure.” Under the 2026 drug price revision, ratings of individual companies based on corporate indicators for evaluating their stable supply systems will be published, and qualifying products will be exempted from price-range consolidation. In addition, the minimum drug prices for products that meet the deviation rate requirements were raised again, as in the previous year. To create and maintain an appropriate competitive environment for generics, the government also decided that authorized generics (AGs) newly listed from October 2026 onward will be priced the same as brand-name drugs. With regard to the co-payment system for drugs, the co-payment amount for elective care using long-listed drugs (products listed on the NHI drug price list for an extended period) has been increased from one-fourth to one-half of the price difference. It was also decided that one-fourth of the drug cost for some OTC-like drugs will not be covered by insurance. In addition, the “Basic Policy on Economic and Fiscal Management and Reform 2026 (Basic Policy 2026)” approved by the Cabinet in July 2026 states that the government will maintain the stable supply of generic drugs, etc. by promoting industrial structural reform.

Under these circumstances, in order to fulfill our responsibility for stable supply, we are working to further increase production capacity in the domestic generics business. As the third solid formulation building at the Yamagata Plant began full-scale operation in October 2025, the annual production capacity of the three plants increased to 17.5 billion tablets in FY2026. To help alleviate pharmaceutical supply instability, which has become a social concern, in January 2026, we concluded a basic agreement with Otsuka Pharmaceutical Co., Ltd. to establish a strategic cooperative framework for drug manufacturing. Furthermore, in April 2026, we agreed with Adragos Pharma Kawagoe K.K. and Sanwa Kagaku Kenkyusho Co., Ltd. to collaborate on the stable supply of off-patent drugs. In addition, in July 2026, we announced the acquisition of shares of Tanabe Pharma Factory Co., Ltd. (hereinafter referred to as “Tanabe Pharma Factory”) from Tanabe Pharma Corporation, as well as the transfer of manufacturing and marketing approvals. In the future, Tanabe Pharma Factory will make capital investments to increase production and aim for a production capacity of 4 to 5 billion tablets in FY2036. By combining the production capacity of Tanabe Pharma Factory with increased production through larger equipment and improved production efficiency at our three plants, as well as contract manufacturing volumes through collaboration, we plan to achieve production capacity of 24 billion tablets in FY2030 and more than 30 billion tablets in FY2036. In response to challenges facing the pharmaceutical industry, we are working to build a collaborative framework among brand-name drug companies, generic drug companies, and pharmaceutical contract manufacturing companies. We view brand-name drugs and generic drugs whose patent periods have expired as a single off-patent drug market. Through this approach, we aim to create an ecosystem that ensures the sustainable and stable supply of therapeutically necessary drugs and supports a sound cyclical model for society as a whole. In order to bring this concept to life, we will work to secure manufacturing capacity and build a mutual backup system for a stable supply of drugs through collaboration with these companies.

In terms of manufacturing control and quality control, we not only comply with the GMP Ordinance, which is the standard for manufacturing control and quality control of pharmaceuticals, and other related laws and regulations, but also actively adopt international standards such as PIC/S GMP and ICH Guidelines, and work to ensure appropriate quality and safety of pharmaceuticals through our own systems and education and training. In addition to the MES (Manufacturing Execution System) and LIMS (Laboratory Information Management System) already in place, we have introduced a QMS (Quality Management System) to further improve quality control. We will continue our efforts to improve manufacturing control and quality control in order to prevent human errors. Furthermore, in order to maintain and strengthen our stable supply system, we are promoting multiple sourcing of APIs and audits of manufacturing sites, and are continuing to strengthen governance and ensure thorough compliance throughout the entire Group, from API manufacturing to formulation manufacturing, distribution and sales.

On the sales front, in March 2026, we launched “Prasugrel Tablets 2.5 mg/3.75 mg/5 mg ‘Towa’” and “Prasugrel OD Tablets 20 mg ‘Towa’,” representing our second authorized-generic ingredient. In June 2026, 13 new products with eight ingredients were added to the National Health Insurance drug price list, bringing the total number of our generic drugs to 741 products with 317 ingredients (as of June 2026).

As for the development of health-related businesses, in order to respond to new medical systems such as the community-based integrated care system, we focus on the “Healthcare Passport” (that enables local medical professionals and residents to share health and medical information in both directions). We are working to realize the diversified development of health-related businesses by forming synergies between each subsidiary and existing businesses from the viewpoint of treatment, prevention and nursing care support, and increasing products and services for maintaining and promoting health.

In the consolidated results for the three-month period ended June 30, 2026, the domestic segment posted net sales of 55,981 million yen (up 6.1% year on year) and segment profit of 7,013 million yen (up 2.0% year on year), due to an increase in the volume of products supplied to the market as a result of higher production volumes and an increase in unit prices due to an improved sales mix.

(Overseas segment)

In the overseas segment, the Group operates a generic drug business in the European and U.S. markets through Towa INT in order to strengthen and expand its overseas pharmaceutical business. We aim to secure sales and segment profits by maintaining and strengthening existing businesses and further expanding markets and regions, while stepping up investments in R&D and facilities necessary for future growth. One instance of our production synergies paying off can be seen at Towa INT’s Martorelles plant where we manufacture ESOMEPRAZOLE CAPSULES for the Japanese market. We also started joint development as part of efforts to create R&D synergies. We will continue to interact and share information with all our divisions to foster group synergies in development and manufacturing technology. By leveraging Towa INT’s sales network in multiple countries in Europe and the U.S. and its manufacturing bases in Europe that comply with standards in Europe and the U.S., we are working to establish a global business foundation that can provide high-quality, value-added generic drugs to patients worldwide from three regions: Japan, the U.S. and Europe.

For the consolidated results for the three-month period ended June 30, 2026, the overseas segment posted net sales of 15,612 million yen (up 25.0% year on year) and a segment profit of 5 million yen (compared with a segment loss of 562 million yen in the same period of the previous fiscal year). This was due to growth in mainstay products in the European B2C business, and an increase in contract manufacturing in the European B2B business, although the impact of the suspension of sales of mainstay products due to the nitrosamine problem in the U.S. continued.

(2) Overview of financial position during the period

(i) Assets, Liabilities and Net Assets

Total assets at the end of the first quarter were 480,709 million yen, an increase of 5,418 million yen from the end of the previous fiscal year. The main factors were an increase of 4,503 million yen in inventories and an increase of 1,357 million yen in notes and accounts receivable - trade, despite a decrease of 1,589 million yen in property, plant and equipment.

Liabilities were 298,232 million yen, an increase of 1,046 million yen from the end of the previous fiscal year. The main factors were an increase of 4,831 million yen in lease liabilities, an increase of 2,407 million yen in notes and accounts payable - trade, and an increase of 1,665 million yen in short-term borrowings, despite a decrease of 4,158 million yen in long-term borrowings and a decrease of 2,501 million yen in income taxes payable.

Net assets were 182,476 million yen, an increase of 4,372 million yen from the end of the previous fiscal year. The main factors included an increase of 3,553 million yen in retained earnings and an increase of 772 million yen in foreign currency translation adjustments.

As a result, the equity ratio came to 38.0%.

(ii) Cash Flows

The balance of cash and cash equivalents at the end of the period under review was 41,724 million yen, a decrease of 3,086 million yen from the end of the previous fiscal year.

The status of each cash flow in the consolidated three months under review is as follows.

(Cash flows from operating activities)

Net cash provided by operating activities was 729million yen (down 5,163 million yen year on year). This was mainly due to profit before income taxes of 7,943 million yen (up 3,982 million yen year on year) and depreciation of 4,553 million yen (up 409 million yen year on year). These factors more than offset income taxes paid of 4,089 million yen (down 196 million yen year on year), an increase in inventories of 4,339 million yen (up 210 million yen year on year), and a gain on valuation of derivatives of 1,424 million yen (compared with a loss on valuation of derivatives of 1,452 million yen in the same period of the previous fiscal year).

(Cash flows from investing activities)

Net cash used in investing activities was 3,302 million yen (down 1,414 million yen year on year). This was mainly due to purchases of property, plant and equipment of 3,085 million yen (down 1,294 million yen year on year).

(Cash flows from financing activities)

Net cash used in financing activities was 346 million yen (6,253 million yen of net cash provided by financing activities in the same period of the previous fiscal year). This was mainly due to repayments of long-term borrowings of 6,347 million yen (up 3,349 million yen year on year) and dividends paid of 1,887 million yen (up 9 million yen year on year), despite proceeds from sales and leaseback transactions of 3,738 million yen (up 1,659 million yen year on year) and proceeds from long-term borrowings of 3,000 million yen (down 5,500 million yen year on year).

(3) Explanation of consolidated financial forecasts and other forward-looking information

The consolidated earnings forecast for the fiscal year ending March 31, 2027 (for the six-month period and full year), announced on May 14, 2026, has not been revised.

2. Quarterly Consolidated Financial Statements and Key Notes

(1) Consolidated balance sheets

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and deposits	45,306	42,229
Notes and accounts receivable - trade	63,283	64,641
Electronically recorded monetary claims - operating	10,898	10,726
Merchandise and finished goods	54,255	55,968
Work in process	20,038	22,276
Raw materials and supplies	49,132	49,686
Other	24,608	30,238
Allowance for doubtful accounts	(179)	(4)
Total current assets	267,343	275,761
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	86,575	87,906
Machinery, equipment and vehicles, net	20,458	20,112
Land	18,586	18,628
Leased assets, net	12,921	17,184
Construction in progress	27,387	20,636
Other, net	4,715	4,585
Total property, plant and equipment	170,643	169,054
Intangible assets		
Goodwill	9,468	9,004
Other	17,211	16,824
Total intangible assets	26,680	25,828
Investments and other assets		
Investment securities	957	1,039
Other	10,538	9,879
Allowance for doubtful accounts	(873)	(854)
Total investments and other assets	10,622	10,064
Total non-current assets	207,946	204,947
Total assets	475,290	480,709

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	21,309	23,717
Electronically recorded obligations - operating	12,034	11,886
Short-term borrowings	7,100	8,766
Current portion of long-term borrowings	21,772	22,625
Lease liabilities	1,699	2,138
Income taxes payable	4,766	2,265
Provisions	97	49
Other	28,086	26,298
Total current liabilities	96,867	97,747
Non-current liabilities		
Long-term borrowings	183,335	179,177
Lease liabilities	12,829	17,221
Retirement benefit liability	132	147
Other	4,019	3,938
Total non-current liabilities	200,318	200,485
Total liabilities	297,186	298,232
Net assets		
Shareholders' equity		
Share capital	4,717	4,717
Capital surplus	7,842	7,842
Retained earnings	151,815	155,368
Treasury shares	(5,584)	(5,584)
Total shareholders' equity	158,790	162,343
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	323	370
Foreign currency translation adjustment	18,989	19,762
Total accumulated other comprehensive income	19,313	20,132
Total net assets	178,103	182,476
Total liabilities and net assets	475,290	480,709

(2) Consolidated statements of income (cumulative) and consolidated statements of comprehensive income (cumulative)

Consolidated statements of income (cumulative)

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Net sales	65,149	71,380
Cost of sales	41,474	45,281
Gross profit	23,674	26,099
Selling, general and administrative expenses	18,468	19,579
Operating profit	5,206	6,519
Non-operating income		
Interest income	61	68
Dividend income	6	7
Foreign exchange gains	373	342
Gain on valuation of derivatives	—	1,424
Other	329	441
Total non-operating income	769	2,284
Non-operating expenses		
Interest expenses	540	628
Loss on valuation of derivatives	1,452	—
Litigation expenses	20	197
Other	10	35
Total non-operating expenses	2,023	862
Ordinary profit	3,953	7,941
Extraordinary income		
Gain on sale of non-current assets	9	2
Other	0	—
Total extraordinary income	9	2
Extraordinary losses		
Loss on disposal of non-current assets	1	0
Total extraordinary losses	1	0
Profit before income taxes	3,960	7,943
Income taxes	1,447	2,412
Profit	2,513	5,531
Profit attributable to owners of parent	2,513	5,531

Consolidated statements of comprehensive income (cumulative)

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Profit	2,513	5,531
Other comprehensive income		
Valuation difference on available-for-sale securities	(11)	46
Foreign currency translation adjustment	563	772
Total other comprehensive income	552	819
Comprehensive income	3,065	6,350
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	3,065	6,350
Comprehensive income attributable to non-controlling interests	—	—

(3) Consolidated statements of cash flows

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities		
Profit before income taxes	3,960	7,943
Depreciation	4,144	4,553
Amortization of goodwill	1,105	509
Increase (decrease) in allowance for doubtful accounts	(161)	(195)
Increase (decrease) in other provisions	(56)	(34)
Loss (gain) on sale of non-current assets	(9)	(2)
Loss (gain) on disposal of non-current assets	1	0
Interest and dividend income	(67)	(76)
Interest expenses	540	628
Loss (gain) on valuation of derivatives	1,452	(1,424)
Decrease (increase) in trade receivables	2,699	(914)
Decrease (increase) in inventories	(4,129)	(4,339)
Increase (decrease) in trade payables	1,690	2,207
Other, net	(550)	(3,675)
Subtotal	10,620	5,179
Interest and dividends received	75	64
Interest paid	(524)	(604)
Compensation received	0	15
Subsidies received	6	164
Income taxes refund (paid)	(4,286)	(4,089)
Net cash provided by (used in) operating activities	5,892	729
Cash flows from investing activities		
Purchase of property, plant and equipment	(4,380)	(3,085)
Purchase of intangible assets	(229)	(299)
Other, net	(108)	82
Net cash provided by (used in) investing activities	(4,717)	(3,302)
Cash flows from financing activities		
Increase (decrease) in short-term borrowings	953	1,633
Proceeds from long-term borrowings	8,500	3,000
Repayments of long-term borrowings	(2,998)	(6,347)
Redemption of straight bonds	(39)	—
Dividends paid	(1,878)	(1,887)
Repayments of lease liabilities	(364)	(474)
Proceeds from sales and leaseback transactions	2,079	3,738
Other, net	—	(8)
Net cash provided by (used in) financing activities	6,253	(346)
Effect of exchange rate change on cash and cash equivalents	50	(166)
Net increase (decrease) in cash and cash equivalents	7,478	(3,086)
Cash and cash equivalents at beginning of period	45,460	44,811
Cash and cash equivalents at end of period	52,938	41,724

(4) Notes to consolidated financial statements

(Notes on segment information)

Information concerning net sales and profit (loss) by reportable segment

For three months ended June 30, 2025

(Millions of yen)

	Reportable segment			Adjustment (Note 1)	Total (Note 2)
	Domestic	Overseas	Subtotal		
Sales					
Sales to outside customers	52,780	12,369	65,149	—	65,149
Sales or transfers between segments	—	122	122	(122)	—
Total	52,780	12,492	65,272	(122)	65,149
Segment profit (loss)	6,873	(562)	6,310	(1,104)	5,206

Notes: 1. Adjustment in segment profit (loss) represents goodwill amortization of (1,105) million yen, and elimination of internal transactions between segments of 1 million yen.

2. Segment profit (loss) matches operating profit on the consolidated statements of income.

For three months ended June 30, 2026

(Millions of yen)

	Reportable segment			Adjustment (Note 1)	Total (Note 2)
	Domestic	Overseas	Subtotal		
Sales					
Sales to outside customers	55,981	15,399	71,380	—	71,380
Sales or transfers between segments	—	213	213	(213)	—
Total	55,981	15,612	71,593	(213)	71,380
Segment profit	7,013	5	7,018	(499)	6,519

Notes: 1. Adjustment in segment profit represents goodwill amortization of (509) million yen, and elimination of internal transactions between segments of 9 million yen.

2. Segment profit matches operating profit on the consolidated statements of income.

(Notes on significant changes in the amount of shareholders' equity)

Not applicable.

(Notes on going concern assumption)

Not applicable.